Intellia Therapeutics Valuation Multiples

Intellia Therapeutics Overview

About Intellia Therapeutics

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It’s evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Founded

2014

HQ

Employees

403

Website

intelliatx.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $66M

EBITDA: ($418M)

EV

$1B

Valuation Multiples

Multiples.vc

Start free trial

Intellia Therapeutics Financials

Intellia Therapeutics reported last 12-month revenue of $66M and negative EBITDA of ($418M).

In the same LTM period, Intellia Therapeutics generated $66M in gross profit, ($418M) in EBITDA losses, and had net loss of ($419M).

Intellia Therapeutics P&L

In the most recent fiscal year, Intellia Therapeutics reported revenue of $68M and EBITDA of ($414M).

Intellia Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX

Intellia Therapeutics Stock Performance

Intellia Therapeutics has current market cap of $2B, and enterprise value of $1B.

Intellia Therapeutics' stock price is $15.45.

Intellia Therapeutics Valuation Multiples

Intellia Therapeutics trades at 20.9x EV/Revenue multiple, and (3.3x) EV/EBITDA.

Intellia Therapeutics Financial Valuation Multiples

As of March 21, 2026, Intellia Therapeutics has market cap of $2B and EV of $1B.

Equity research analysts estimate Intellia Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Intellia Therapeutics has a P/E ratio of (4.3x).

Intellia Therapeutics Margins & Growth Rates

Intellia Therapeutics' revenue in the last 12 month grew by 54%.

Intellia Therapeutics' revenue per employee in the last FY averaged $0.2M.

Intellia Therapeutics' rule of 40 is (581%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Intellia Therapeutics' rule of X is (500%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Intellia Therapeutics Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Intellia Therapeutics M&A Activity

Intellia Therapeutics acquired XXX companies to date.

Last acquisition by Intellia Therapeutics was on XXXXXXXX, XXXXX. Intellia Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Intellia Therapeutics Investment Activity

Intellia Therapeutics invested in XXX companies to date.

Intellia Therapeutics made its latest investment on XXXXXXXX, XXXXX. Intellia Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).